Igf2bp1, insulin-like growth factor 2 mRNA-binding protein 1, is an oncofetal RNA-binding protein. Its main function is to stabilize target transcripts by protecting them from miRNA-mediated degradation. It is involved in various biological processes, especially in cancer-related pathways, and has been linked to the progression of multiple cancer types [3].

In cancer research, studies have shown diverse roles of Igf2bp1. In liver cancer, PRMT3-mediated arginine methylation of Igf2bp1 at R452 promotes oxaliplatin resistance, as it stabilizes the mRNA of HEG1, an effector of the PRMT3-Igf2bp1 axis [1]. In endometrial cancer, Igf2bp1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner, promoting cancer cell proliferation, regulating the cell cycle, and driving cancer progression [2]. In breast cancer, USP10 stabilizes Igf2bp1, which then binds to and stabilizes CPT1A mRNA, promoting breast cancer metastasis [4]. In esophageal squamous cell carcinoma, Igf2bp1 binds and stabilizes INHBA mRNA, activating the Smad2/3 signaling pathway and promoting cell invasion and migration [5]. In non-small cell lung cancer, the lncRNA MNX1-AS1 drives phase separation of Igf2bp1, increasing the stability of c-Myc and E2F1 mRNA and promoting cell-cycle progression and proliferation [6]. In bladder cancer, circFAM13B competitively binds to Igf2bp1, reducing its binding to PKM2 3'UTR, decreasing PKM2 mRNA stability, inhibiting glycolysis, and enhancing immunotherapy sensitivity [7].

In summary, Igf2bp1 plays a crucial role in multiple cancer-related biological processes. These findings from in vivo and in vitro functional studies, though not specifically from KO/CKO mouse models in the provided references, highlight its significance in cancer development, progression, and response to therapy, suggesting that Igf2bp1 could be a potential therapeutic target in various cancers.